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ABSTRACT Zaire ebolavirus (EBOV), Bundibugyo ebolavirus (BDBV), and Reston ebola-
virus (RESTV) belong to the same genus but exhibit different virulence properties.
VP24 protein, a structural protein present in all family members, blocks interferon
(IFN) signaling and likely contributes to virulence. Inhibition of IFN signaling by
EBOV VP24 (eVP24) involves its interaction with the NPI-1 subfamily of karyopherin
alpha (KPNA) nuclear transporters. Here, we evaluated eVP24, BDBV VP24 (bVP24),
and RESTV VP24 (rVP24) interactions with three NPI-1 subfamily KPNAs (KPNA1,
KPNA5, and KPNA6). Using puriﬁed proteins, we demonstrated that each VP24 binds
to each of the three NPI-1 KPNAs. bVP24, however, exhibited approximately 10-fold-
lower KPNA binding afﬁnity than either eVP24 or rVP24. Cell-based assays also indi-
cate that bVP24 exhibits decreased KPNA interaction, decreased suppression of IFN
induced gene expression, and a decreased half-life in transfected cells compared to
eVP24 or rVP24. Amino acid sequence alignments between bVP24 and eVP24 also
identiﬁed residues within and surrounding the previously deﬁned eVP24-KPNA5
binding interface that decrease eVP24-KPNA afﬁnity or bVP24-KPNA afﬁnity. VP24
mutations that lead to reduced KPNA binding afﬁnity also decrease IFN inhibition
and shorten VP24 half-lives. These data identify novel functional differences in VP24-
KPNA interaction and reveal a novel impact of the VP24-KPNA interaction on VP24
stability.
IMPORTANCE The interaction of Ebola virus (EBOV) VP24 protein with host karyopherin
alpha (KPNA) proteins blocks type I interferon (IFN) signaling, which is a central
component of the host innate immune response to viral infection. Here, we quanti-
tatively compared the interactions of VP24 proteins from EBOV and two members of
the Ebolavirus genus, Bundibugyo virus (BDBV) and Reston virus (RESTV). The data
reveal lower binding afﬁnity of the BDBV VP24 (bVP24) for KPNAs and demonstrate
that the interaction with KPNA modulates inhibition of IFN signaling and VP24 sta-
bility. The effect of KPNA interaction on VP24 stability is a novel functional conse-
quence of this virus-host interaction, and the differences identiﬁed between viral
species may contribute to differences in pathogenesis.
KEYWORDS STAT1, ebola virus, ﬁlovirus, interferons, karyopherin, protein stability
The ﬁlovirus family is comprised of three genera, Ebolavirus, Marburgvirus, andCuevavirus. Within the Ebolavirus genus are ﬁve species: Zaire ebolavirus (also
known as Ebola virus [EBOV]), Sudan ebolavirus, Bundibugyo ebolavirus, Tai Forrest
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ebolavirus, and Reston ebolavirus (1). EBOV has been associated with multiple outbreaks
of lethal human disease, including the 2014 West African epidemic that resulted in
approximately 28,000 infections and 11,000 deaths (2). Other members of the genus
have displayed various degrees of virulence. Notably, outbreaks due to Bundibugyo
virus (BDBV) resulted in case fatality rates of approximately 30%, a ﬁgure lower than
that seen in EBOV outbreaks (3). Moreover, BDBV was also less lethal than EBOV in
nonhuman primate studies (4). Despite exposure of individuals to infected animals and
evidence of seroconversion in humans, Reston virus (RESTV) stands out for never having
caused documented human disease, suggesting that RESTV is of low virulence in
humans (5).
The molecular determinants of virulence and replication efﬁciency of members
within the Ebolavirus genus remain incompletely deﬁned. However, the capacity of
these viruses to suppress interferon (IFN) responses is thought to contribute to their
pathogenesis (6). One viral protein that functions as a suppressor of IFN responses is
VP24 (6). VP24 is a viral structural protein that also inﬂuences viral particle infectivity,
virus host range, and viral RNA synthesis (7–16). EBOV VP24 (eVP24), RESTV VP24
(rVP24), and the VP24 of Lloviu virus, an as-yet-uncultured virus classiﬁed in the genus
Cuevavirus, all inhibit IFN-induced gene expression, whereas VP24s from members of
the Marburgvirus genus do not (17–22). Previous studies demonstrated that eVP24
competes with tyrosine-phosphorylated STAT1 (PY-STAT1) for interaction with the
NPI-1 subfamily of karyopherin alphas (KPNA): KPNA1, KPNA5, and KPNA6 (18, 19, 21).
This results in a block in PY-STAT1 nuclear import by the KPNAs, leading to inhibition
of IFN-induced gene expression and impaired antiviral activity. Structural studies
deﬁned the eVP24-binding interface with KPNA5 and allowed testing of the competi-
tive inhibition model (21). These studies also deﬁned a high-afﬁnity target site for VP24s
on KPNAs that overlaps the binding site for the nonclassical nuclear localization signal
(ncNLS) used by PY-STAT1.
Although eVP24 inhibition of IFN signaling has been studied in detail, it has been
unclear whether the VP24s from different ebolavirus species differ in how they interact
with KPNAs and whether any differences have functional consequences. Here, we
compared the VP24s from EBOV, BDBV, and RESTV, viruses with different virulence
proﬁles in humans. We demonstrate different afﬁnities of the VP24s for the NPI-1
subfamily KPNAs, with BDBV VP24 (bVP24) in particular exhibiting lower afﬁnities than
either eVP24 or rVP24. This correlates with a relatively reduced level of inhibition of IFN
signaling by bVP24. In addition, bVP24 accumulates to lower levels in transfected cells
than does eVP24 or rVP24, corresponding to a shorter bVP24 half-life. bVP24 can be
stabilized, however, by overexpression of NPI-1 subfamily KNPAs. Assessments using
KPNA and eVP24 mutants with different binding afﬁnities support the idea of a direct
inﬂuence of KPNA interaction on VP24 stability. These ﬁndings provide a novel expla-
nation of the functional consequence of the interaction between VP24 and KPNA.
RESULTS
bVP24 binds to the same KPNAs as do eVP24 and rVP24. To examine the
efﬁciencies with which eVP24, rVP24, and bVP24 bind to the NPI-1 subfamily of KPNAs,
coimmunoprecipitation (coIP) experiments with Flag-tagged KPNAs and hemagglutinin
(HA)-tagged VP24s were performed. As a positive control, an HA-eVP24-Flag-KPNA5
coIP was included. As a negative control, HA-tagged Marburg virus VP24 (mVP24) was
used because it does not interact with KPNAs (22). eVP24, rVP24, and bVP24 were each
found to interact with KPNA1 (Fig. 1A), KPNA5 (Fig. 1B), and KPNA6 (Fig. 1C). None of
the VP24s detectably interacted with the non-NPI-1 KPNA2 (Fig. 1D). Notable in these
experiments was the lower efﬁciency of bVP24 pulldown, particularly with KPNA1 (Fig.
1A) and KPNA5 (Fig. 1B). bVP24 also accumulated to lower levels in the whole-cell
extracts than eVP24 or rVP24. These differences were most pronounced in the absence
of KPNA overexpression. Further, when KPNA1, KPNA5, or KPNA6 was coexpressed, the
signal of bVP24 in the whole-cell extracts, relative to that of eVP24 or rVP24, was
increased.
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bVP24 binds to KPNA1, KPNA5, and KPNA6 with reduced afﬁnities in compar-
ison to eVP24 and rVP24. The dissociation constants (KD) for eVP24, rVP24, and bVP24
interaction with KPNAs were quantiﬁed with biolayer interferometry (BLI) (see Fig. S1 in
the supplemental material). eVP24 bound KPNA1, KPNA5, and KPNA6 with dissociation
constants of 13.3  3.9 nM, 9.77  1.2 nM, and 5.33  1.5 nM, respectively (Table 1).
The afﬁnities of bVP24 for the three KPNAs were 5-fold to 10-fold weaker than those of
eVP24, binding KPNA1 with a KD of 69.7  11 nM, KPNA5 with a KD of 43.3  7.1 nM,
and KPNA6 with a KD of 49.0  4.2 nM (Table 1). The afﬁnities of rVP24 for KPNA1,
KPNA5, and KPNA6, at 5.23  2.6 nM, 7.07  2.5 nM, and 3.17  1.3 nM, respectively,
were similar to those of eVP24 (Table 1).
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FIG 1 eVP24, rVP24, and bVP24 coprecipitate with each member of the NPI-1 subfamily of KPNAs. (A) VP24 coprecipita-
tions with KPNA1. Empty expression plasmid (E) and HA-tagged eVP24, rVP24, bVP24, or mVP24 were transfected alone
or in combination with KPNA5 or KPNA1, as indicated. Shown are Western blots of whole-cell extracts (WCE) or anti-Flag
immunoprecipitates (IP:Flag). KPNAs were detected by blotting with anti-Flag antibody, and VP24 proteins were detected
by blotting with anti-HA antibody. WCEs were blotted with anti--tubulin (TubB) as a loading control. The interaction of
KPNA5 with eVP24 and the absence of interaction of KPNA5 with mVP24 served as positive and negative controls,
respectively. (B) VP24 coprecipitations with KPNA5. (C) VP24 coprecipitations with KPNA6. (D) Absence of VP24 interactions
with KPNA2.
TABLE 1 Afﬁnities of VP24 proteins for members of the NPI-1 subfamily of KPNAs
Protein
KD (nM)a
KPNA1 KPNA5 KPNA6
eVP24 13.3 3.9 9.77 1.2 5.33 1.5
bVP24 69.7 11 43.3 7.1 49.0 4.2
rVP24 5.23 2.6 7.07 2.5 3.17 1.3
aData represent the means and standard deviations of results from three experiments.
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bVP24 shows reduced inhibition of IFN-induced gene expression relative to
eVP24 or rVP24. Next, we assessed the three VP24s for their potency of IFN signaling
inhibition. Following transfection of cells with empty vector or HA-tagged VP24 and an
ISG54 promoter reporter plasmid, cells were treated with IFN- and reporter activity
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FIG 2 Impact of VP24s on IFN-induced gene expression. (A) The effect of expressing HA-tagged eVP24,
rVP24, or bVP24 on IFN--induced expression of an ISG54 promoter reporter gene was assessed. Cells
were transfected with empty vector (E) or 100 ng, 10 ng, or 1 ng of VP24 expression plasmid (decreasing
concentrations are indicated by the wedges), an ISG54 promoter-ﬁreﬂy luciferase reporter plasmid, and
a constitutively expressed Renilla luciferase plasmid. IFN- was added after an overnight incubation, and
luciferase values were measured 24 h later. Columns are representative of the means and error bars represent
the standard deviations of results from two biological replicates each, including three technical replicates of
each condition. Statistical signiﬁcance was assessed by Student’s t test. For eVP24 at 100 ng versus rVP24 at
100 ng, the single asterisk (*) represents P 0.029; for eVP24 at 10 ng versus bVP24 at 10 ng, double asterisks
(**) represent P  0.0054; for eVP24 at 100 ng versus bVP24 at 100 ng, the single asterisk (*) represents P 
0.0276. (B) Cell lysates from the experiment whose results are shown in panel A were assayed by Western
blotting for HA-VP24 expression (anti-HA) and -tubulin expression (anti-TubB).
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FIG 3 VP24 protein stability is modulated upon coexpression of interacting KPNAs. (A) Abundance of eVP24 in the presence of KPNA1, KPNA5, or KPNA6.
293T cells were transfected with the indicated plasmids and were treated at 24 h posttransfection with cycloheximide (CHX). Starting at time zero,
protein lysates were harvested and analyzed by Western blotting (WB) to detect Flag-tagged KPNA, HA-tagged VP24, or -tubulin (TubB), as indicated.
(B) Abundance of eVP24 in the presence of KPNA2. (C) Abundance of bVP24 in the presence of KPNA1, KPNA5, or KPNA6. (D) Abundance of bVP24 in
the presence of KPNA2. (E) Abundance of rVP24 in the presence of KPNA1, KPNA5, or KPNA6. (F) Abundance of rVP24 in the presence of KPNA2.
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was assessed. While bVP24 efﬁciently inhibited ISG54 reporter activity at higher con-
centrations, the level of this inhibition was reduced more quickly than that seen with
eVP24 or rVP24 at lower concentrations of the protein (Fig. 2A). rVP24 functional
activity was similar to that of eVP24, consistent with the KPNA binding data (Fig. 2A)
and data from a previous study (19). These ﬁndings are consistent with a model where
the lower bVP24 binding afﬁnity for KPNAs results in less-efﬁcient IFN inhibition.
However, it should also be noted that bVP24 once again appeared to accumulate to
lower levels than did eVP24 and rVP24 (Fig. 2B).
bVP24 displays a shorter half-life than eVP24. Next, VP24 half-life was quantiﬁed
in the absence or presence of interacting KPNAs. Transfected cells were treated with an
inhibitor of protein synthesis, cycloheximide (CHX), and protein lysates were examined
for VP24 expression at several time points. Protein was followed over an 8-h time period
(Fig. 3), and Western blot signals were quantiﬁed and plotted (Fig. 4). In the absence of
KPNA overexpression, eVP24 levels modestly decreased by 8 h post-CHX addition. This
loss of signal was mostly reversed when KPNA1, KPNA5, or KPNA6 was coexpressed
(Fig. 3A and 4A). In contrast, expression of noninteracting KPNA2 did not result in
increased eVP24 half-life (Fig. 3B and 4A). bVP24 exhibited a shorter half-life in
comparison to eVP24, and its stability also increased upon coexpression of the NPI-1
bVP24
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FIG 4 Densitometric analysis demonstrates that KPNA expression modulates eVP24 and bVP24 stability.
VP24 abundance over time was measured relative to time zero, and half-live values were calculated by
measuring the band intensity using Bio-Rad Image Lab software. VP24 band intensity over time was
normalized to -tubulin band intensity. The dotted black line indicates the 50% point. Data points
represent two biological replicates. Protein half-life was calculated by the best-ﬁt curve to the data
points. Half-life decay curves for bVP24 (A), eVP24 (B), and rVP24 (C) are shown.
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subfamily KPNAs (Fig. 3C and 4B) but not KPNA2 (Fig. 3D and 4B). Interestingly, rVP24
levels in the absence of KPNA overexpression were high at the beginning of the time
course but did drop over time. rVP24 remained relatively stable in the presence of
KPNA1, KPNA2, or KPNA6. However, total levels were lower and stability was decreased
in the presence of KPNA5 in both experiments (Fig. 3E and F and 4C). These data
suggest that interactions with KPNAs can modulate VP24 stability.
To address the hypothesis that the lower KPNA binding afﬁnity might account for
the instability of VP24 in the absence of overexpressed KPNA and for its enhanced
stability upon KPNA expression, we tested the half-live values of previously described
eVP24 mutants with decreased KPNA binding afﬁnities (21). eVP24 cluster 1A and 1C
mutants were previously shown by coimmunoprecipitation to be substantially impaired
for interaction with KPNA5 (21), while eVP24 cluster 1D mutant weakly interacted with
KPNA5 (Fig. 5A). As shown by BLI, weak binding between the three eVP24 cluster
mutants and KPNA1, KPNA5, and KPNA6 occurred at the highest concentration (2 M)
of eVP24 tested; however, a steady-state dissociation constant could not be deter-
mined, indicating dissociation constants for the mutant eVP24s much larger than those
for the wild-type (WT) eVP24 (Fig. S2). The eVP24 mutants had a shorter half-life than
WT eVP24, with the eVP24 cluster 1A mutant exhibiting the most rapid loss of signal
(Fig. 5B). Coexpressed with KPNA5, the half-life of eVP24 cluster 1A mutant was
substantially extended, whereas expression of KPNA2, which does not interact, failed to
enhance eVP24 cluster 1A mutant stability (Fig. 5C). A separate experiment, performed
to quantify the levels of the different VP24s, substantiated these conclusions (Fig. 5D).
These data suggest that binding to KPNA protects eVP24 from degradation and that
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FIG 5 eVP24 residues that are critical for KPNA binding also inﬂuence eVP24 protein stability. (A)
Previously described eVP24 constructs possessing mutations that impair binding to KPNA. (B) Abundance
of WT HA-eVP24 (eVP24) or the indicated HA-eVP24 mutants in transfected cells treated with cyclohex-
imide (CHX). Western blotting to detect Flag-tagged KPNA, HA-tagged VP24, or -tubulin (TubB) was
performed at the indicated times post-CHX addition. (C) Abundance of HA-eVP24 1A mutant in the
presence or absence of Flag-tagged KPNA2 or Flag-tagged KPNA5. (D) Densitometric analysis of WT
HA-tagged eVP24 or the indicated HA-tagged eVP24 mutants over an 8-h time frame. Data points
represent two biological replicates, and the dotted black line indicates the point at which 50% of the
protein remains.
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weaker binding of eVP24 to KPNA can be compensated for with increased expression
of KPNA.
To further correlate KPNA binding with VP24 half-life, the stabilities of eVP24 and
bVP24 were compared in the absence or presence of WT or mutant KPNA5s that were
previously described as being diminished for eVP24 interaction. The KPNA mutants
tested included F484A, Y477G, or the KPNA5 ARM10 mutant containing four amino acid
changes (Fig. 6A) (21). As described above, eVP24 was once again more stable than
bVP24 (Fig. 6B). The levels of expression of the KPNA5 mutants were similar over the 8-h
CHX treatment (Fig. 6C). In contrast to the outcome seen when WT KPNA5 was
expressed, the interaction-defective KPNAs did not enhance bVP24 stability (Fig. 6D).
For eVP24, which is already relatively stable, expression of WT KPNA5 once again
resulted in modestly enhanced stability whereas, particularly for the ARM10 KPNA5
mutant, eVP24 stability was clearly lower (Fig. 6E).
To address the impact of endogenous KPNA expression on VP24 stability, we
measured VP24 half-life in cells that were transfected with small interfering RNAs
(siRNAs) targeting the NPI-1 KPNA subfamily. siRNAs speciﬁc for KPNA1, KPNA5, and
KPNA6 (si3xRNA) were simultaneously transfected into cells followed by the sequential
transfection of VP24 24 h later. As a negative control, cells were transfected with a
nonspeciﬁc siRNA (siScramble). Only reduction of KPNA5 and KPNA6 was achieved in
the cells transfected with siRNAs targeting all three NPI-1 subfamily KPNAs (Fig. 7A).
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FIG 6 Stabilization of VP24 requires interaction with KPNA. (A) Previously described KPNA5 constructs
possessing mutations in ARM domain 10 that impair interaction with eVP24. (B) Protein stability of
HA-eVP24 or HA-bVP24 transfected alone. Western blotting to detect Flag-tagged KPNA, HA-tagged
VP24, or -tubulin (TubB) was performed at the indicated times post-CHX addition. (C) Abundance of the
indicated Flag-KPNA5 mutants after CHX addition when transfected alone. (D) Stabilities of HA-bVP24
coexpressed with either WT Flag-KPNA5 or the indicated mutants. (E) Stabilities of HA-eVP24
coexpressed with either WT Flag-KPNA5 or the indicated mutants. For panels C to E, labeling is as
described for panel B.
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Despite the expression of endogenous KPNA1 in these cells, the eVP24 and bVP24
half-live values were reduced in comparison to those seen with the cells transfected
with siScramble (Fig. 7B and C). rVP24 protein stability was also reduced modestly (Fig.
7D). Together, these data suggest that endogenous KPNA levels modulate VP24
stability.
Molecular basis for differential KPNA binding by eVP24 and bVP24. We next
sought to clarify the basis for the differential levels of KPNA binding by bVP24 and
eVP24. Although bVP24 and eVP24 are highly conserved (86% identity at the amino
acid level), analysis of the eVP24/KPNA5 structure indicated that several nonconserved
residues are located at the interface (Fig. 8A to C). To identify nonconserved
residues located in hot spots for association between eVP24 and KPNA5, the
cocrystal structure of eVP24 and KPNA5 C terminus (PDB 4U2X) was analyzed by
HyPare (http://bip.weizmann.ac.il/HyPare), an algorithm that calculates the impact of
mutations on the afﬁnity between two interacting proteins (23). This process identiﬁed
eVP24 residues N135, R140, and V141 (bVP24 residues Q135, H140, and A141) (Fig. 8D).
To examine the contribution of these residues to the differential levels of afﬁnity of
eVP24 and bVP24 for KPNAs, we mutated eVP24 residues at positions 135, 140, and 141
to the analogous residues found in bVP24. We also performed the reciprocal mutagen-
esis, making bVP24 more eVP24-like. An additional nonconserved residue at position 83
was also included in this analysis. We therefore generated mutants eVP24 4x (eVP24
P83S/N135Q/R140H/V141A) and bVP24 4x (bVP24 S83P/Q135N/H140R/A141V) (Table 2).
The afﬁnities of these two mutant proteins for the three KPNAs, as determined by BLI,
were similar to those of the WT VP24 proteins (Fig. S3). eVP24 4x bound KPNA1, KPNA5,
and KPNA6 with dissociation constants of 22.0 5.2 nM, 14.0 2.1 nM, and 7.63 1.2
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FIG 7 VP24 half-life is altered in cells transfected with siRNA targeting the NPI-1 KPNA subfamily. (A)
Following transfection of a scrambled siRNA or pooled siRNAs to knock down KPNA1, KPNA5, and KPNA6
(si3XRNA), Western blotting was performed to detect KPNA1, KPNA5, or KPNA6 or all three simultane-
ously (KPNA1, KPNA5, and KPNA6). -Tubulin Western blots served as a loading control. (B to D) Protein
half-life decay curves for bVP24 (B), eVP24 (C), and rVP24 (D). VP24 abundance was measured over time
in cells transfected with either a scrambled control siRNA or siRNAs targeting the three members of the
NPI-1 subfamily of KPNAs (si3xRNA). GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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nM, respectively, while bVP24 4x bound KPNA1 with a KD of 103  14 nM, KPNA5 with
a KD of 57.0  10 nM, and KPNA6 with a KD of 85.0  14 nM, representing a less than
1-fold decrease in afﬁnity in all cases (Tables 1 and 2). This suggests that, although three
of these residues were identiﬁed by HyPare analysis to be important for the interaction
between eVP24 and KPNA5, they do not determine the differing afﬁnities of eVP24 and
bVP24 for the KPNAs. To verify that these residues were important for the interaction
of VP24 with KPNA, we mutated positions 83, 135, and 140 to alanine and position 141
eVP24 1   MAKATGRYNL ISPKKDLEKG VVLSDLCNFL VSQTIQGWKV YWAGIEFDVT HKGMALLHRL KTNDFAPAWS MTRNLFPHLF QNPNSTIESP 90
bVP24 1   MAKATGRYNL VSPKKDLERG LVLSDLCTFL VDQTIQGWRV TWVGIEFDIA QKGMALLHRL KTADFAPAWS MTRNLFPHLF QNSNSTIESP 90
rVP24 1   MAKATGRYNL VPPKKDMEKG VIFSDLCNFL ITQTLQGWKV YWAGIEFDVS QKGMALLTRL KTNDFAPAWA MTRNLFPHLF QNPNSVIQSP 90
eVP24 91  LWALRVILAA GIQDQLIDQS LIEPLAGALG LISDWLLTTN TNHFNMRTQR VKEQLSLKML SLIRSNILKF INKLDALHVV NYNGLLSSIE 180
bVP24 91  LWALRVILAA GIQDQLIDQS LVEPLAGALS LVSDWLLTTN TNHFQMRTQH AKEQLSLKML SLVRSNILKF ISQLDALHVV NYNGLLSSIE 180
rVP24 91  IWALRVILAA GLQDQLLDHS LVEPLTGALG LISDWLLTTT STHFNLRTRS VKDQLSLRML SLIRSNILQF INKLDALHVV NYNGLLSSIE 180
eVP24 181 IGTQNHTIII TRTNMGFLVE LQEPDKSAMN RMKPGPAKFS LLHESTLKAF TQGSSTRMQS LILEFNSSLA I 251
bVP24 181 IGTRNHTIII TRTNMGFLVE LQEPDKSAMN QKKPGPVKFS LLHESTFKAL IKKPATKMQA LILEFNSSLA I 251 
rVP24 181 IGTSTHTIII TRTNMGFLVE VQEPDKSAMN SKRPGPVKFS LLHESAFKPF TRVPQSGMQS LIMEFNSLLA I 251 
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FIG 8 Comparison of the eVP24 and bVP24 KPNA5 binding interfaces. (A) Structure of the eVP24 (blue and purple) and KPNA5C (orange)
(PDB 4U2X) complex with KPNA5C aligned with KPNA1 (light orange) (PDB 3TJ3). Residues conserved between eVP24 and bVP24 are
indicated in blue, while nonconserved residues are highlighted in purple. N and C indicate the N terminus and C terminus, respectively.
(B) Closeup view (corresponding to the dotted box in panel A) of the interface between eVP24 and KPNA5. Residues P83, N135, R140, and
V141 are indicated in purple with side chains. (C) Sequence comparison of eVP24, bVP24, and rVP24 proteins. Alignment of VP24 protein
sequences was performed using the Cobalt constraint-based multiple protein alignment tool. Zaire ebolavirus VP24 (eVP24) (NCBI
accession number AF086833.2), Reston ebolavirus VP24 (rVP24) (NCBI accession number AF522874.1), and Bundibugyo ebolavirus VP24
(bVP24) (NCBI accession number NC_014373.1) were used in the alignment. Conserved residues are indicated in red, and those not
conserved are in blue. The eVP24-KPNA5 binding interfaces identiﬁed by Xu et al. (21), comprising cluster 1, cluster 2, and cluster 3, are
highlighted in yellow. (D) HyPare analysis of the interaction between eVP24 and KPNA5. Changes in relative levels of binding afﬁnity
between eVP24 and KPNA5 are indicated for the predicted outcome of mutating eVP24 residues 16 to 231 to basic residues (lysine [Lys]
or arginine [Arg]) (purple line), acidic residues (aspartate [Asp] or glutamate [Glu]) (green line), or alanine (Ala) residues (gray line). The
dashed lines indicate the location of residues N135, R140, and V141. Residue P83 was not present in the HyPare analysis. A representation
of an alignment of eVP24 and bVP24 residues 1 to 251 is shown at the bottom of the graph, with red indicating conserved residues and
blue indicating nonconserved residues.
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to glycine, generating eVP24 4xA (eVP24 P83A/N135A/R140A/V141G) and bVP24 4xA
(bVP24 S83A/Q135A/H140A/A141G). The afﬁnities of these mutants for KPNA1, KPNA5,
and KPNA6 were tested using BLI (Fig. S3). A signiﬁcant decrease in afﬁnity for all three
KPNA proteins in comparison to the WT level was detected, with eVP24 4xA binding the
three KPNAs with 8-fold to 16-fold-lower afﬁnity than WT eVP24 and bVP24 4xA binding
the KPNAs with 7-fold-lower afﬁnity than WT bVP24. This indicates that one or more of
these residues are important for the interaction of VP24 and KPNA (Table 2). Together,
these data suggest that while the interaction between VP24 proteins and KPNA is
evolutionarily conserved across members of the Ebolavirus genus, there is a level of
plasticity and redundancy allowed in the amino acids present in these positions.
Next, we tested the effect of mutating residues at positions 83, 135, 140, and 141 on
eVP24 and bVP24 IFN inhibition. The mutants included eVP24 4x, eVP24 4xA, eVP24
N135Q, bVP24 H140R/A141V, bVP24 Q135N, and bVP24 R184Q (Fig. 9A and B). The
bVP24 R184Q mutant was included in these studies because this residue is located in
TABLE 2 Afﬁnities of mutant eVP24 and bVP24 proteins for members of the NPI-1
subfamily of KPNAs
Protein
KD (nM)a
KPNA1 KPNA5 KPNA6
eVP24 4x 22.0 5.2 14.0 2.1 7.63 1.3
eVP24 4xA 150 21 96.7 7.6 92.0 13
bVP24 4x 103 14 57.0 10 85.0 14
bVP24 4xA 560 25 376 36 420 19
bVP24 Q135N 60.3 2.0 41.1 4.0 42.0 3.3
bVP24 Q135A 98.3 3.4 64.0 6.5 99.0 4.8
aData represent the means and standard deviations of results from three experiments.
E
eVP24 bVP24
0
20
40
200
400
600
800
1000
**
*
**
E
Q135NR184Q140/141
+ IFNβ
C.
200
400
600
800
1000
0
5
10
15
20
25
E
eVP24bVP24
E
4x 4xA
+ IFNβ
N135Q
D.
eVP24 mutants bVP24 mutants
A.
N135Q
eVP24 mutants
4x - P83S/N135Q/R140H/V141A
4xA - P83A/N135A/R140A/V141G
140/141 - H140R/A141V
bVP24 mutants
R184Q
Q135N
B.
F
ol
d 
C
ha
ng
e
 IS
G
54
 P
ro
m
ot
er
 In
du
ct
io
n
F
ol
d 
C
ha
ng
e
 IS
G
54
 P
ro
m
ot
er
 In
du
ct
io
n
anti-HA VP24anti-HA VP24
anti-TubB anti-TubB
*
** **
*
**
FIG 9 Nonconserved interface residues dictate the potency of IFN antagonism by eVP24 and bVP24. (A and B) eVP24 (A) and bVP24 (B) mutants used for the
experiments represented in this ﬁgure. (C) Suppression of IFN-induced ISG54 promoter activity upon expression of bVP24 or eVP24 or the indicated eVP24
mutants with residues changed to correspond to bVP24 residue identities. (D) Suppression of IFN-induced ISG54 promoter activity upon expression of eVP24
or bVP24 or the indicated bVP24 mutants with residues changed to correspond to eVP24. Transfections and reporter gene assays were performed as described
for Fig. 2. Columns are representative of the means and error bars represent the standard deviations of results from two biological replicates each with three
technical replicates performed for each transfection condition. Statistical signiﬁcance was assessed by Student’s t test, comparing the chimeric VP24 change
in reporter activity to that obtained with the corresponding wild-type VP24 plasmid concentration (**, P  0.1; ***, P  0.01).
Schwarz et al. Journal of Virology
February 2017 Volume 91 Issue 4 e01715-16 jvi.asm.org 10
 o
n
 M
ay 16, 2017 by W
ashington University in St. Louis
http://jvi.asm.org/
D
ow
nloaded from
 
the eVP24 cluster 2 KPNA binding interface and is not conserved between eVP24 and
bVP24 (Fig. 8C). Cells were transfected with an ISG54 reporter plasmid and empty
vector or HA-tagged VP24 proteins as indicated and treated with IFN-, after which
reporter activity was assessed. While eVP24 4x inhibited ISG54 reporter activity to a
level similar to that seen with WT eVP24 at the highest concentration, this inhibition
decreased more rapidly as VP24 levels were reduced (Fig. 9C). Mutation of the four
positions in eVP24 4xA resulted in a loss of inhibition compared to WT eVP24, even at
the highest concentration (Fig. 9C). bVP24 mutant H140R/A141V behaved like WT
bVP24 (Fig. 9D), consistent with the minimal impact of these residues on binding
afﬁnities when combined in the bVP24 4xA mutant. Likewise, bVP24 R184Q inhibited
ISG54 activity similarly to WT bVP24 (Fig. 9D). The single point mutation Q135N resulted
in a modest gain of inhibitory activity for bVP24, despite the lack of increased binding
afﬁnity for the KPNAs or of an obvious change in expression levels (Fig. 9D and Table
2). Conversely, the reciprocal N135Q mutation did not decrease eVP24 inhibitory
activity (Fig. 9C). This suggests that in vitro binding data may not fully account for the
IFN inhibitory activities of VP24s.
DISCUSSION
In this study, we identiﬁed previously unrecognized differences in how VP24 pro-
teins from three ebolavirus species interact with KPNAs. The differences inﬂuence IFN
inhibitory activity and VP24 stability, affecting the weaker binding bVP24 most dra-
matically. eVP24 was originally established as a viral immune antagonist that blocks IFN
signaling by inhibiting the nuclear import of PY-STAT1 (18, 19). The discovery of this
anti-IFN signaling function correlated with eVP24 binding to the KPNA1 nuclear import
factor. KPNA1 had been described as the mediator of PY-STAT1 nuclear import, with
this import being mediated via a nonclassical NLS. PY-STAT1 nuclear import is critical
to allow PY-STAT1 to stimulate the transcription of interferon-stimulated genes (ISGs)
and create an antiviral state (24, 25). In the presence of excess eVP24, the interaction
between KPNA1 and PY-STAT1 was found to be disrupted, thereby preventing ISG
expression (18, 19). Subsequent studies demonstrated that eVP24 and PY-STAT1 can
interact with all three members of the NPI-1 subfamily of KPNAs: KPNA1, KPNA5, and
KPNA6 (19, 26, 27).
KPNAs possess an N-terminal importin-beta binding domain, 10 armadillo (ARM)
repeats, and a C-terminal CAS binding site. ARM2 to ARM4 and ARM6 to ARM8 are
responsible for binding to classical mono- and bipartite basic NLSs, whereas dimerized
PY-STAT1 interacts more C-terminally within a region encompassing ARM8 to ARM9
(25). Mapping studies of KPNA1 indicated that eVP24 binds at a site that partially
overlaps the PY-STAT1 ncNLS binding site (19). Consistent with this observation, an
X-ray cocrystal structure demonstrated the interaction of eVP24 with a large binding
interface encompassing ARM8 to ARM10 in the C terminus of KPNA5 (21). Mutagenesis
studies, based on the eVP24-KPNA5 structural data, demonstrated that loss of this
interaction results in loss of inhibition of IFN-induced PY-STAT1 nuclear import and loss
of inhibition of IFN-induced ISG expression. These data, along with data from coIP and
in vitro binding studies, all point to a competition binding model of eVP24 antagonism
of IFN signaling (21). Given this model, it was of interest to determine whether afﬁnities
of a given VP24 vary between the three different NPI-1 KPNAs. It was also of interest to
determine whether VP24s from different ebolavirus species exhibit various degrees of
interaction with KPNAs, as this might result in altered degrees of IFN antagonism.
Previous studies established that VP24s from a mouse-adapted EBOV and from
REBOV also interacted with members of the NPI-1 subfamily of KPNAs from human and
mouse (19). The mouse-adapted eVP24 amino acid sequence differs by only one amino
acid from the parental version of eVP24, whereas rVP24 shares 82% amino acid identity
with eVP24 (data not shown). The conservation of KPNA binding activity, despite
sequence divergence, suggests a biologically important role for the VP24-KPNA inter-
action. The coIP assays used to demonstrate these interactions were not quantitative,
however, prompting us here to compare KPNA binding afﬁnities using puriﬁed, recom-
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binant versions of eVP24, rVP24, and bVP24. bVP24 was chosen because its sequence
is also divergent from that of eVP24, exhibiting 86% amino acid identity to eVP24 (data
not shown), and because BDBV exhibits attenuation in human outbreaks and in
nonhuman primate models relative to EBOV (3, 4). Our results demonstrate that the
afﬁnities for KPNA1, KPNA5, and KPNA6 are very similar for a given VP24 but that, while
eVP24 and rVP24 exhibit similar KPNA binding afﬁnities, bVP24 binding represents
lower afﬁnity. Comparable afﬁnities of the VP24 proteins across the NPI-1 KPNAs would
allow the virus to block IFN signaling at equal levels regardless of the ratio of NPI-1
family members present in the cell. However, the impaired binding of bVP24 for each
KPNA suggested possible functional differences.
Evaluation of the sequences of eVP24 and bVP24 (Fig. 8) identiﬁed several differ-
ences at the primary sequence level that may impact interactions between KPNAs and
VP24 proteins. Our studies show that mutating eVP24 residues to those found in bVP24
results in limited perturbations to binding afﬁnity or IFN antagonism. Importantly,
mutation of these same residues to alanine in either eVP24 or bVP24 results in an
approximately 10-fold decrease in afﬁnity. Our data are consistent with the following
two conclusions. First, the interface between eVP24 and KPNA is highly redundant and
is therefore able to accept multiple mutations without signiﬁcant loss of binding
afﬁnity. Second, although the binding interface is redundant and may accommodate
multiple interactions, we observed side chain preferences, as the alanine mutations in
either eVP24 or bVP24 appear to lose about 10-fold to 15-fold afﬁnity for KPNA.
The different KPNA binding afﬁnities are of functional signiﬁcance. rVP24 shows
modestly higher binding afﬁnity than does eVP24 for each of the KPNAs (Table 1). This
correlates with very similar capacities of eVP24 and rVP24 for suppression of IFN-
induced gene expression in titration studies. In contrast, the signiﬁcantly lower bVP24
binding afﬁnity with KPNA correlates with slightly impaired suppression of IFN re-
sponses at lower concentrations, although binding is sufﬁcient to inhibit IFN-induced
gene expression at higher concentrations. VP24 proteins also play other roles over the
course of the viral replication cycle. VP24, in cooperation with NP and VP35, promotes
the formation of nucleocapsid structures and is necessary for newly formed virus
particles to be infectious; VP24 also modulates viral RNA synthesis and serves as a host
range determinant, although the impact of VP24 on viral RNA synthesis in the context
of EBOV infection has been questioned (8, 10, 12–15). Therefore, functional effects of
the KPNA interaction on VP24 that extend beyond suppression of IFN responses are of
interest. Here, we demonstrate that KPNA has a stabilizing effect on VP24 that may have
implications for multiple VP24 functions. The impact of KPNA on stability is most
apparent with lower-binding-afﬁnity VP24s. Expressed alone, bVP24 displays a short
protein half-life relative to eVP24 and rVP24, as demonstrated by pulse-chase experi-
ments. VP24 half-life is inversely correlated to KPNA binding afﬁnity, as eVP24 proteins
with mutations in the KPNA binding interface were also demonstrated to have higher
protein turnover than eVP24 or rVP24. Interestingly, when coexpressed with any of the
mutant or wild-type eVP24 or bVP24 proteins, only the members of the NPI-1 subfamily
of KPNAs had a stabilizing effect on VP24. Conversely, rVP24 appeared to decrease in
protein concentration when coexpressed with KPNA5, suggesting that this stabilizing
effect could be speciﬁc to certain members of the Ebolavirus genus and that KPNA5
may have a unique impact on rVP24. Future studies will need to be performed to
determine how KPNA might inﬂuence other VP24 functions in the context of virus
replication.
An important issue raised by these observations is whether the differences detected
impact virulence. While the determinants of ﬁlovirus pathogenesis are incompletely
deﬁned, robust viral replication and modulation of the innate immune responses are
important (14, 28, 29). For example, VP35 mutations that abrogate its inhibition of IFN
production result in attenuation of the virus in vivo and in vitro (28, 30–32). In addition,
adaptation of EBOV and Marburg virus (MARV) to animal models involves mutations
within their respective IFN signaling antagonists, VP24 and VP40, to enhance virulence
(15, 16, 19, 29, 33). High levels of viral replication would also require robust packaging
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of the viral genomes to make infectious particles. The substantial similarities between
eVP24 and rVP24 in terms of NPI-1 binding afﬁnities and capacity to suppress IFN
signaling would argue against the VP24 IFN-antagonist function playing a signiﬁcant
role in virulence differences. The differences between bVP24 and either eVP24 or rVP24
are more intriguing. The lower IFN-antagonist function detected in our transfection
studies, which were seen when smaller amounts of bVP24 plasmid were transfected,
might result in increased sensitivity to IFNs early in infection, before substantial bVP24
levels have accumulated. If bVP24 is also less stable in infected cells, then this might
impact multiple viral functions. It will therefore be important to examine the role of
bVP24 during the course of BDBV infection in vivo.
Although ﬁloviruses are primarily of concern as causes of severe human disease,
their evolution as zoonotic pathogens has presumably occurred in nonhuman species.
As bats have been implicated as the host reservoir for ﬁloviruses, the interaction
between KPNA and VP24 most likely evolved in these mammals (34, 35). While the
Egyptian fruit bat (Rousettus aegyptiacus) is believed to act as a reservoir host for
Marburg virus, the identities of reservoir hosts for different Ebolavirus species have not
been deﬁnitively identiﬁed (36). It is likely that the reservoir hosts differ for EBOV,
RESTV, and BDBV, which would explain differential interactions with human KPNAs.
Taking KPNA5 as an example, the KPNAs are well conserved between humans and bats.
However, there are differences, with KPNAs from different bats exhibiting different
degrees of amino acid identity. Bats can be divided into two large groups, the
microbats and megabats. Human KPNA5 shares 95.9% amino acid identity with KPNA5
from a microbat (Myotis luciﬁgus) and 98.1% with KPNA5 from a megabat (Pteropus
vampyrus) (data not shown). It will be of interest, as reservoir hosts are better deﬁned,
to compare VP24-KPNA interactions across different reservoir and nonreservoir mam-
malian species and determine how these differences in host proteins might inﬂuence
virulence.
The lack of effective antivirals limits the clinical options available to treat ﬁlovirus
infections of humans. Because VP24 has roles in innate immune evasion and virus
assembly, it is a potential therapeutic target. To date, speciﬁc information has been
available regarding the structure of eVP24, rVP24, Sudan virus (SUDV) VP24, and eVP24
in complex with KPNA5 (21, 37, 38). As it is a nonenzymatic protein, therapeutic
targeting may require destabilization of VP24 or disruption of functionally important
interactions with host or viral factors. In support of the idea of VP24 as a therapeutic
target, phosphorodiamidate morpholino oligomers that target VP24 can protect ex-
perimentally infected nonhistone proteins (NHPs) from lethal EBOV challenge (39).
Although the eVP24-KPNA5 interface poses challenges due to the fact that it has a large
surface area (21), the data in this study highlight potential synergistic effects of
disruption of the interaction. Speciﬁcally, one could abrogate the viral block to the
antiviral effects of IFNs while also decreasing VP24 stability. The reduced levels of VP24
would therefore impact assembly of virus particles and potentially decrease the infec-
tivity of the virus particles that are produced. For these reasons, efforts to target this
interaction are warranted.
MATERIALS AND METHODS
Plasmids. The pCAGGS base plasmid was used for expression of viral proteins in mammalian cells.
Point mutations were generated using the overlap PCR method and were veriﬁed by sequencing.
Sequences were based on the following: eVP24 (NCBI accession number AGB56798.1); rVP24 (NCBI
accession number AY769362); bVP24 (NCBI accession number NC_014373 [but codon optimized for
mammalian expression]); KPNA1 (NCBI accession number NM_002264.3); KPNA5 (NCBI accession number
NP_002260.2); and KPNA6 (NCBI accession number NM_012316.4). For recombinant protein expression
in Escherichia coli, eVP24 11-237, bVP24 11-237, rVP24 11-237, and mutant VP24 constructs were
subcloned into a modiﬁed pET15b vector (Novagen, EMD Millipore, Billerica, MA), while KPNA1 61-512,
KPNA5 66-513, and KPNA6 66-510 were subcloned into a modiﬁed pET15b vector (Novagen, EMD
Millipore, Billerica, MA) containing an AviTag, which contains the target amino acid sequence for
biotinylation (Avidity LLC, Aurora, CO).
Recombinant protein expression, puriﬁcation, and biotinylation. Proteins were overexpressed as
maltose binding protein (MBP) fusion proteins in BL21(DE3) E. coli cells (Novagen, EMD Millipore, Billerica,
MA) in LB medium. Cells were harvested and resuspended in buffer containing 25 mM sodium phosphate
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(pH 7.5), 250 mM NaCl, 20 mM imidazole, and 5 mM 2-mercaptoethanol and were lysed using an
EmulsiFlex-C5 homogenizer (Avestin, Ottawa, Canada). Lysates were clariﬁed by centrifugation at
42,000  g at 10°C for 40 min. Proteins were puriﬁed using a series of chromatographic columns, and
sample purity was determined by SDS-PAGE.
MBP-Avi-KPNA1, MBP-Avi-KPNA5, and MBP-Avi-KPNA6 were biotinylated using BirA ligase (Avidity
LLC, Aurora, CO) and the following reaction conditions: 40 M MBP-Avi-KPNA1 (or MBP-Avi-KPNA5 or
MBP-Avi-KPNA6), 50 mM bicine buffer (pH 8.3), 10 mM ATP, 10 mM magnesium acetate, 50 M D-biotin,
and 1 mg/ml BirA ligase (Avidity LLC, Aurora, CO). The reaction was allowed to proceed for 1 h at room
temperature, after which the biotinylated proteins were injected onto a Superdex 200 gel ﬁltration
column (GE Healthcare Life Sciences, Pittsburgh, PA). Sample purity was determined by SDS-PAGE.
Biolayer interferometry (BLI) binding studies. BLI experiments were performed using an Octet RED
system (Pall ForteBio LLC, Menlo Park, CA) and buffer containing 10 mM HEPES (pH 7.5), 300 mM NaCl,
2 mM TCEP [tris(2-carboxyethyl)phosphine], 0.5% bovine serum albumin (BSA), and 0.02% Tween 20.
Biotinylated KPNA proteins were immobilized on streptavidin sensors for 400 s. Association and disso-
ciation of VP24 proteins were analyzed over a range of concentrations (2-fold serial dilutions) over the
course of the experiment. In brief, for each concentration of VP24, protein association was measured for
300 s, followed by dissociation for 600 s in buffer. Steady-state analysis was performed using Octet
software (version 8.2.0.7), and the resulting data represent the mean steady-state dissociation constants
(KD) and standard deviations across three experiments.
Coimmunoprecipitation assays. Human embryonic kidney 293T (HEK293T) cells were transfected
with the indicated plasmids by using Lipofectamine 2000 (Thermo Fisher Scientiﬁc, Waltham, MA), and
at 24 h posttransfection, cells were lysed in NP-40 lysis buffer (50 mM Tris [pH 7.5], 280 mM NaCl, 0.5%
Nonidet P-40, 0.2 mM EDTA, 2 mM EGTA, 10% glycerol, protease inhibitor [cOmplete; Roche,
Indianapolis, IN]). Anti-Flag M2 magnetic beads were incubated with lysates for 1 h at 4°C, washed
ﬁve times in NP-40 lysis buffer, and eluted using 3 Flag peptide (Sigma-Aldrich, St. Louis, MO) at
4°C for 30 min.
Reporter gene assay. HEK293T cells were transfected with an ISG54 ﬁreﬂy luciferase reporter
plasmid, a constitutively active Renilla luciferase reporter plasmid (pRL-tk) (Promega, Madison, WI), and
the indicated expression plasmids. At 24 h posttransfection, the cells were treated with 1,000 U/ml
human IFN- (PBL Assay Science, Piscataway, NJ)–Dulbecco’s modiﬁed Eagle’s medium (DMEM)–10%
fetal bovine serum. At 24 h posttreatment, cells were lysed and a dual luciferase reporter assay (Promega,
Madison, WI) was performed. Fireﬂy luciferase values were normalized to Renilla luciferase values.
Statistical signiﬁcance was assessed using Student’s t test.
VP24 half-life analysis. HEK293T cells were transfected with the indicated plasmids, and at 24 h
posttransfection, cells were treated with 100 g/ml of the translational inhibitor cycloheximide (CHX) for
the indicated time periods. Starting at time zero post-CHX treatment, cells were lysed in NP-40 lysis buffer
and proteins were resolved by SDS-PAGE. VP24 half-live values were calculated by measuring band
intensity using Bio-Rad Image Lab software. Brieﬂy, band intensities for VP24 and beta-tubulin from
each time point were measured and compared to those measured at time zero post-cycloheximide
treatment. VP24 band intensity was normalized to the beta-tubulin band intensity from each
respective time point.
HEK293T cells were transfected with siRNA directed against members of the NPI-1 subfamily of
KPNA (si3xKPNA). A 30 nM concentration of ON-TARGETplus SMARTpool (Dharmacon) siRNA directed
against KPNA1, KPNA5, and KPNA6 was transfected into 293T cells using RNAiMAX (Qiagen). At 24
h post-siRNA transfection, cells were trypsinized, resuspended, and transfected with the indicated
VP24 plasmids. At 24 h post-plasmid transfection, cells were treated with CHX and analyzed as
described above.
Antibodies. Monoclonal mouse anti-Flag M2 antibody, polyclonal rabbit anti-Flag antibody, mono-
clonal mouse anti-HA antibody, and polyclonal rabbit anti-HA antibody were all purchased from
Sigma-Aldrich (St. Louis, MO). Monoclonal mouse anti-KPNA antibodies (against KPNA1, KPNA2, KPNA5,
and KPNA6) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
JVI.01715-16.
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